
|Videos|May 16, 2014
Personalized Therapies in Advanced Breast Cancer
Author(s)Debu Tripathy, MD
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses new personalized therapies on the horizon for advanced breast cancer.
Advertisement
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses new personalized therapies on the horizon for advanced breast cancer.
Clinical Pearls:
- Physicians have known for some time that there are molecular targets that are amenable to therapy
- Now that the entire genome can be sequenced, physicians are understanding more about mutations in breast cancer
- Upon sequencing the tumors of many patients with breast cancer, physicians are finding that no two tumors are the same
- New mutations may be picked up after analyzing a patient’s tumor after treatment
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Rezatapopt Shows 46% ORR in TP53 Y220C–Mutated Ovarian Cancer
2
First-Line Savolitinib/Osimertinib Improves PFS in MET+ NSCLC
3
Hypoxia Tracer Gets FDA Breakthrough Status in HPV+ Oropharyngeal Cancer
4
G2032R Resistance Data Is Reshaping Second-Line Sequencing in ROS1+ NSCLC
5
































